الفهرس 
Chroniic Lymphocytic LeukemiiaOnly 14 pages are availabe for public view
 |  | from | 161 |  |  |
| | | from | 161 | | |
Abstract
CLL is a lymphoid malignancy characterized by monoclonal expansion of B lymphocytes in the peripheral blood, bone marrow, and lymphoid organs. The disease has a typical clinical presentation but the clinical course is variable with survival time from 3 to 20 years.Two major staging systems (Binet and Rai) have been developed to address this clinical heterogeneity, they are based on the degree of bone marrow insufficiency (anemia, thrombocytopenia), lymphadenopathy, and hepatosplenomegaly.Lymphoid Enhancer-Binding factor-1 (LEF-1) is a 48-kD nuclear protein that is expressed in pro-B cells and mature T cells but not in mature B cell (Howe and Bromidge, 2006 and Gutierrez et al ., 2010) . LEF-1binds to a functionally important site in the T-cell receptor alpha (TCRα)enhancer and confers maximal enhancer activity; LEF-1 belongs to a family of regulatory proteins that share homology with high mobility group protein-1 (HMG1). (Okamura et al., 1998 and Reya et al., 2000).Lymphoid Enhancer-Binding factor-1 (LEF-1) is highly associated with CLL/SLL among small B-cell lymphomas, Beside that LEF-1 has been shown to be down regulated in NK cells because LEF-1 and TCF-1 (T-cell–specific transcription factor) play a redundant role in the regulation of NK cells and it is believed that TCF activity is up regulated, while LEF-1 is suppressed in normal NK cells (Held et al., 2003).The aim of this study is to evaluate the role of Lymphoid Enhancer-Binding factor-1 (LEF-1) expression by flow cytometry in patients with chronic lymphocytic leukemia